» Articles » PMID: 17485642

ATP13A2 Missense Mutations in Juvenile Parkinsonism and Young Onset Parkinson Disease

Abstract

Objective: To assess the prevalence, nature, and associated phenotypes of ATP13A2 gene mutations among patients with juvenile parkinsonism (onset <21 years) or young onset (between 21 and 40 years) Parkinson disease (YOPD).

Methods: We studied 46 patients, mostly from Italy or Brazil, including 11 with juvenile parkinsonism and 35 with YOPD. Thirty-three cases were sporadic and 13 had positive family history compatible with autosomal recessive inheritance. Forty-two had only parkinsonian signs, while four (all juvenile-onset) had multisystemic involvement. The whole ATP13A2 coding region (29 exons) and exon-intron boundaries were sequenced from genomic DNA.

Results: A novel homozygous missense mutation (Gly504Arg) was identified in one sporadic case from Brazil with juvenile parkinsonism. This patient had symptoms onset at age 12, levodopa-responsive severe akinetic-rigid parkinsonism, levodopa-induced motor fluctuations and dyskinesias, severe visual hallucinations, and supranuclear vertical gaze paresis, but no pyramidal deficit nor dementia. Brain CT scan showed moderate diffuse atrophy. Furthermore, two Italian cases with YOPD without atypical features carried a novel missense mutation (Thr12Met, Gly533Arg) in single heterozygous state.

Conclusions: We confirm that ATP13A2 homozygous mutations are associated with human parkinsonism, and expand the associated genotypic and clinical spectrum, by describing a homozygous missense mutation in this gene in a patient with a phenotype milder than that initially associated with ATP13A2 mutations (Kufor-Rakeb syndrome). Our data also suggest that ATP13A2 single heterozygous mutations might be etiologically relevant for patients with YOPD and further studies of this gene in Parkinson disease are warranted.

Citing Articles

Adult-onset deletion of ATP13A2 in mice induces progressive nigrostriatal pathway dopaminergic degeneration and lysosomal abnormalities.

Erb M, Sipple K, Levine N, Chen X, Moore D NPJ Parkinsons Dis. 2024; 10(1):133.

PMID: 39030200 PMC: 11271504. DOI: 10.1038/s41531-024-00748-5.


Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine.

Wang Q, Gu X, Yang L, Jiang Y, Zhang J, He J Front Aging Neurosci. 2024; 16:1417515.

PMID: 39026991 PMC: 11254646. DOI: 10.3389/fnagi.2024.1417515.


Kufor-Rakeb syndrome-associated psychosis: a novel loss-of-function ATP13A2 variant and response to antipsychotic therapy.

Colijn M, Vrijsen S, Au P, Abou El Asrar R, Houdou M, Van den Haute C Neurogenetics. 2024; 25(4):405-415.

PMID: 39023817 PMC: 11534834. DOI: 10.1007/s10048-024-00767-7.


ATP13A2 (PARK9) and basal ganglia function.

Croucher K, Fleming S Front Neurol. 2024; 14:1252400.

PMID: 38249738 PMC: 10796451. DOI: 10.3389/fneur.2023.1252400.


Manganese-Induced Parkinsonism: Evidence from Epidemiological and Experimental Studies.

Lucchini R, Tieu K Biomolecules. 2023; 13(8).

PMID: 37627255 PMC: 10452806. DOI: 10.3390/biom13081190.